Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study. / Vest, Stine Dahl; Mikkelsen, Lauge Hjorth; Holm, Frederik; Rasmussen, Peter Kristian; Hindso, Tine Gadegaard; Knudsen, Marina K.H.; Coupland, Sarah E.; Esmaeli, Bita; Finger, Paul T.; Graue, Gerardo F.; Grossniklaus, Hans E.; Honavar, Santosh G.; Mulay, Kaustubh; Sjö, Lene D.; Sniegowski, Matthew C.; Vemuganti, Geeta K.; Thuro, Bradley A.; Heegaard, Steffen.

In: American Journal of Ophthalmology, Vol. 219, 2020, p. 107-120.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Vest, SD, Mikkelsen, LH, Holm, F, Rasmussen, PK, Hindso, TG, Knudsen, MKH, Coupland, SE, Esmaeli, B, Finger, PT, Graue, GF, Grossniklaus, HE, Honavar, SG, Mulay, K, Sjö, LD, Sniegowski, MC, Vemuganti, GK, Thuro, BA & Heegaard, S 2020, 'Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study', American Journal of Ophthalmology, vol. 219, pp. 107-120. https://doi.org/10.1016/j.ajo.2020.06.015

APA

Vest, S. D., Mikkelsen, L. H., Holm, F., Rasmussen, P. K., Hindso, T. G., Knudsen, M. K. H., Coupland, S. E., Esmaeli, B., Finger, P. T., Graue, G. F., Grossniklaus, H. E., Honavar, S. G., Mulay, K., Sjö, L. D., Sniegowski, M. C., Vemuganti, G. K., Thuro, B. A., & Heegaard, S. (2020). Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study. American Journal of Ophthalmology, 219, 107-120. https://doi.org/10.1016/j.ajo.2020.06.015

Vancouver

Vest SD, Mikkelsen LH, Holm F, Rasmussen PK, Hindso TG, Knudsen MKH et al. Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study. American Journal of Ophthalmology. 2020;219:107-120. https://doi.org/10.1016/j.ajo.2020.06.015

Author

Vest, Stine Dahl ; Mikkelsen, Lauge Hjorth ; Holm, Frederik ; Rasmussen, Peter Kristian ; Hindso, Tine Gadegaard ; Knudsen, Marina K.H. ; Coupland, Sarah E. ; Esmaeli, Bita ; Finger, Paul T. ; Graue, Gerardo F. ; Grossniklaus, Hans E. ; Honavar, Santosh G. ; Mulay, Kaustubh ; Sjö, Lene D. ; Sniegowski, Matthew C. ; Vemuganti, Geeta K. ; Thuro, Bradley A. ; Heegaard, Steffen. / Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study. In: American Journal of Ophthalmology. 2020 ; Vol. 219. pp. 107-120.

Bibtex

@article{2c2a830ffb0e4e968d197dcdabcb3ca8,
title = "Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study",
abstract = "Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival. Design: Multicenter retrospective interventional case series. Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980, through December 31, 2017. All patients with histologically verified primary or secondary lymphoma of the lacrimal gland were included. Primary endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A total of 260 patients with lacrimal gland lymphoma were identified. The median age was 58 years and 52% of patients were men. Non-Hodgkin B-cell lymphomas constituted 99% (n = 258) and T-cell lymphomas constituted 1% (n = 2). The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n = 177, 68%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-cell lymphoma (DLBCL) (n = 25, 10%), and mantle cell lymphoma (MCL) (n = 17, 7%). Low-grade lymphomas (EMZL and FL) were most commonly treated with external beam radiotherapy (EBRT), whereas high-grade lymphomas (DLBCL and MCL) were treated with chemotherapy in combination with rituximab and/or EBRT. The prognosis was relatively good with a 5-year OS and DSS of 73.8% and 87.5%, respectively. Lymphoma subtype was a statistically significant predictor for DSS, with EMZL (5-year DSS: 93.4%) having the best prognosis and DLBCL (5-year DSS: 52.6%) having the poorest. Conclusions: This is the largest reported collection of data of subtype-specific lacrimal gland lymphoma. The subtype distribution of lacrimal gland lymphoma resembles that of the ocular adnexa. Prognosis is good and the histologic subtype is a significant predictor for disease-specific survival.",
author = "Vest, {Stine Dahl} and Mikkelsen, {Lauge Hjorth} and Frederik Holm and Rasmussen, {Peter Kristian} and Hindso, {Tine Gadegaard} and Knudsen, {Marina K.H.} and Coupland, {Sarah E.} and Bita Esmaeli and Finger, {Paul T.} and Graue, {Gerardo F.} and Grossniklaus, {Hans E.} and Honavar, {Santosh G.} and Kaustubh Mulay and Sj{\"o}, {Lene D.} and Sniegowski, {Matthew C.} and Vemuganti, {Geeta K.} and Thuro, {Bradley A.} and Steffen Heegaard",
year = "2020",
doi = "10.1016/j.ajo.2020.06.015",
language = "English",
volume = "219",
pages = "107--120",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Lymphoma of the Lacrimal Gland — An International Multicenter Retrospective Study

AU - Vest, Stine Dahl

AU - Mikkelsen, Lauge Hjorth

AU - Holm, Frederik

AU - Rasmussen, Peter Kristian

AU - Hindso, Tine Gadegaard

AU - Knudsen, Marina K.H.

AU - Coupland, Sarah E.

AU - Esmaeli, Bita

AU - Finger, Paul T.

AU - Graue, Gerardo F.

AU - Grossniklaus, Hans E.

AU - Honavar, Santosh G.

AU - Mulay, Kaustubh

AU - Sjö, Lene D.

AU - Sniegowski, Matthew C.

AU - Vemuganti, Geeta K.

AU - Thuro, Bradley A.

AU - Heegaard, Steffen

PY - 2020

Y1 - 2020

N2 - Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival. Design: Multicenter retrospective interventional case series. Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980, through December 31, 2017. All patients with histologically verified primary or secondary lymphoma of the lacrimal gland were included. Primary endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A total of 260 patients with lacrimal gland lymphoma were identified. The median age was 58 years and 52% of patients were men. Non-Hodgkin B-cell lymphomas constituted 99% (n = 258) and T-cell lymphomas constituted 1% (n = 2). The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n = 177, 68%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-cell lymphoma (DLBCL) (n = 25, 10%), and mantle cell lymphoma (MCL) (n = 17, 7%). Low-grade lymphomas (EMZL and FL) were most commonly treated with external beam radiotherapy (EBRT), whereas high-grade lymphomas (DLBCL and MCL) were treated with chemotherapy in combination with rituximab and/or EBRT. The prognosis was relatively good with a 5-year OS and DSS of 73.8% and 87.5%, respectively. Lymphoma subtype was a statistically significant predictor for DSS, with EMZL (5-year DSS: 93.4%) having the best prognosis and DLBCL (5-year DSS: 52.6%) having the poorest. Conclusions: This is the largest reported collection of data of subtype-specific lacrimal gland lymphoma. The subtype distribution of lacrimal gland lymphoma resembles that of the ocular adnexa. Prognosis is good and the histologic subtype is a significant predictor for disease-specific survival.

AB - Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival. Design: Multicenter retrospective interventional case series. Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980, through December 31, 2017. All patients with histologically verified primary or secondary lymphoma of the lacrimal gland were included. Primary endpoints were overall survival (OS) and disease-specific survival (DSS). Results: A total of 260 patients with lacrimal gland lymphoma were identified. The median age was 58 years and 52% of patients were men. Non-Hodgkin B-cell lymphomas constituted 99% (n = 258) and T-cell lymphomas constituted 1% (n = 2). The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n = 177, 68%), follicular lymphoma (FL) (n = 26, 10%), diffuse large B-cell lymphoma (DLBCL) (n = 25, 10%), and mantle cell lymphoma (MCL) (n = 17, 7%). Low-grade lymphomas (EMZL and FL) were most commonly treated with external beam radiotherapy (EBRT), whereas high-grade lymphomas (DLBCL and MCL) were treated with chemotherapy in combination with rituximab and/or EBRT. The prognosis was relatively good with a 5-year OS and DSS of 73.8% and 87.5%, respectively. Lymphoma subtype was a statistically significant predictor for DSS, with EMZL (5-year DSS: 93.4%) having the best prognosis and DLBCL (5-year DSS: 52.6%) having the poorest. Conclusions: This is the largest reported collection of data of subtype-specific lacrimal gland lymphoma. The subtype distribution of lacrimal gland lymphoma resembles that of the ocular adnexa. Prognosis is good and the histologic subtype is a significant predictor for disease-specific survival.

U2 - 10.1016/j.ajo.2020.06.015

DO - 10.1016/j.ajo.2020.06.015

M3 - Journal article

C2 - 32574779

AN - SCOPUS:85090209601

VL - 219

SP - 107

EP - 120

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -

ID: 260197969